Abbott Laboratories (ABT) PEG Ratio: 3.01
Is Abbott Laboratories’s PEG ratio high or low?
Abbott Laboratories's PEG ratio of 3.01 is 245% above its 5-year average of 0.87, near the high end of its 5-year range (0.11–1.99).
The PEG ratio for Abbott Laboratories (ABT) is 3.01. It is above its 12-month average by 2636.36% (0.11).
ABT PEG Ratio Chart
ABT Average PEG Ratio Chart
ABT Current vs Average PEG Ratio Chart
ABT PEG Ratio Metrics
PEG RATIO
3.01
PEG RATIO AVG TTM
0.11
PEG RATIO AVG 3Y
0.36
PEG RATIO AVG 5Y
0.87
PEG RATIO AVG 10Y
0.63
PEG RATIO AVG 15Y
1.98
PEG RATIO AVG 20Y
1.58
CURRENT VS TTM AVG
+2636.36%
CURRENT VS 3Y AVG
+736.11%
CURRENT VS 5Y AVG
+244.99%
CURRENT VS 10Y AVG
+379.05%
CURRENT VS 15Y AVG
+51.85%
CURRENT VS 20Y AVG
+90.04%
ABT Competitors' PEG Ratio
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | $154.66B | 3.01 | 0.11 | 0.36 | 0.87 |
| Gilead Sciences, Inc. (GILD) | $151.21B | 0.01 | 0.01 | 0.38 | 0.25 |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 3.17 | 3.02 | 2.60 | 2.27 |
| Pfizer Inc. (PFE) | $146.36B | N/A | 0.07 | 0.13 | 0.16 |
| Danaher Corporation (DHR) | $130.25B | 89.17 | 1.21 | 1.11 | 1.91 |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 4.51 | 4.57 | 4.57 | 2.77 |
| Amgen Inc. (AMGN) | $183.75B | 0.26 | 0.26 | 2.94 | 2.94 |
| CVS Health Corporation (CVS) | $125.16B | N/A | 0.13 | 1.20 | 1.16 |
| Bristol-Myers Squibb Company (BMY) | $114.14B | 1.67 | 0.24 | 0.24 | 0.18 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.77B | 1.69 | 2.58 | 1.90 | 1.47 |
Growth-Adjusted Valuation
PEG Ratio
3.01
P/E Ratio
24.7
Abbott Laboratories PEG Ratio Formula & Definition
PEG Ratio = PE Ratio / Earnings Growth Rate
The PEG ratio adjusts the PE ratio for expected earnings growth. A PEG near 1 is often considered fairly valued relative to growth.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories PEG Ratio FAQ
- What is the PEG ratio for Abbott Laboratories (ABT)?
- The PEG ratio for ABT stock is 3.01.
- Is Abbott Laboratories's PEG ratio high or low?
- Abbott Laboratories's PEG ratio of 3.01 is 245% above its 5-year average of 0.87, near the high end of its 5-year range (0.11–1.99).
- What is the TTM average PEG ratio for Abbott Laboratories (ABT)?
- The TTM average PEG ratio for ABT stock is 0.11.
- What is the 3Y average PEG ratio for Abbott Laboratories (ABT)?
- The 3Y average PEG ratio for ABT stock is 0.36.
- What is the 5Y average PEG ratio for Abbott Laboratories (ABT)?
- The 5Y average PEG ratio for ABT stock is 0.87.
- What is the 10Y average PEG ratio for Abbott Laboratories (ABT)?
- The 10Y average PEG ratio for ABT stock is 0.63.
- What is the 15Y average PEG ratio for Abbott Laboratories (ABT)?
- The 15Y average PEG ratio for ABT stock is 1.98.
- What is the 20Y average PEG ratio for Abbott Laboratories (ABT)?
- The 20Y average PEG ratio for ABT stock is 1.58.
Abbott Laboratories PEG Ratio History
| DATE | PEG RATIO |
|---|---|
| 2024-12-31 | 0.11 |
| 2021-12-31 | 0.61 |
| 2020-12-31 | 1.99 |
| 2019-12-31 | 0.78 |
| 2018-12-31 | 0.13 |
| 2015-12-31 | 0.15 |
| 2012-12-31 | 0.32 |
| 2011-12-31 | 13.36 |
| 2009-12-31 | 0.39 |
| 2008-12-31 | 0.23 |
| 2007-12-31 | 0.11 |
| 2005-12-31 | 1.80 |
| 2004-12-31 | 0.61 |
| 2002-12-31 | 0.13 |
| 2000-12-31 | 0.92 |
| 1999-12-31 | 2.23 |
| 1998-12-31 | 1.15 |
| 1997-12-31 | 0.95 |
| 1996-12-31 | 0.67 |
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford